TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6775548
Drug: nasogastric saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasogastric saline solution alone
Study: 6775548
Drug: nasogastric saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasogastric saline irrigation with oral mannitol
Study: 6775548
Drug: oral mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral mannitol solution without saline
Study: 31549889
Drug: Venetoclax 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax 400 mg daily plus rituximab
Study: 23684438
Drug: 13 g
Normalized name: UREA 13 g TOPICAL TABLET [CLEAN-UP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13 g ground flaxseed
Study: 19703665
Drug: NanoGreens vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: NanoGreens vegetable supplement drink for 90 days
Study: 16776704
Drug: Rizatriptan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan plus trimebutine (10 mg rizatriptan + 200 mg trimebutine)
Study: 9611401
Drug: Insulin-dependent diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetic patients (European)
Study: 9611401
Drug: Insulin-dependent diabetic
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetic patients with neuropathy (European)
Study: 9611401
Drug: North African
Normalized name: African Pygeum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: North African insulin-dependent diabetic patients
Study: 8406644
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (AMB) 1 mg/kg body weight on alternate days, starting with 0.05 mg/kg on the first day, total dose of 20 mg/kg
Study: 8406644
Drug: Sodium stibogluconate
Normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium stibogluconate (SAG) 20 mg/kg body weight, im daily for 30 days
Study: 3534899
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg maprotiline and 9 mg haloperidol per day (for the first six days)
Study: 3534899
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with maprotiline
Study: 30220648
Drug: BFF MDI
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BFF MDI 320/10 µg
Study: 30220648
Drug: BFF MDI
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BFF MDI 160/10 µg
Study: 25344737
Drug: Flotation tank
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flotation tank treatment
Study: 22733065
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg intravenous oseltamivir
Study: 22733065
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg intravenous oseltamivir
Study: 22733065
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg intravenous oseltamivir
Study: 17218362
Drug: Acetazolamide (ACZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACZ) 250 mg, 3 doses, 8 hours apart
Study: 12232483
Drug: Surgery with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery with total mesorectal excision for T1/2 N0 rectal cancers
Study: 7663010
Drug: Serum levels
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum levels of intercellular adhesion molecule-1 at diagnosis in Hodgkin's disease patients
Study: 7663010
Drug: Serum levels
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum levels of intercellular adhesion molecule-1 in complete remission
Study: 7663010
Drug: Serum levels
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum levels of intercellular adhesion molecule-1 in patients with advanced disease who attained complete remission
Study: 7663010
Drug: Serum levels
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum levels of intercellular adhesion molecule-1 in patients who failed to attain complete remission
Study: 7663010
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of serum levels of intercellular adhesion molecule-1 with clinical features
Study: 782976
Drug: Vaccine A
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine A (with galactose)
Study: 782976
Drug: Vaccine B
Normalized name: meningococcal vaccine B and C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine B (without galactose)
Study: 26848182
Drug: Iron sulfate
Normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iron sulfate (oral)
Study: 26848182
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (intravenous)
Study: 25096309
Drug: 1500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg/day oral glucosamine sulphate
Study: 10463374
Drug: Imipramine (235
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (235 mg/day)
Study: 10463374
Drug: Mirtazapine (77
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (77 mg/day)
Study: 31274485
Drug: Furosemide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (1 mg/kg at induction of anesthesia)
Study: 21486552
Drug: Sankang Capsule
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sankang Capsule
Study: 21486552
Drug: Rhodiola Rosea
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola Rosea Capsule
Study: 21486552
Drug: Shenqi Pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Pollen Capsule
Study: 19271173
Drug: Yixuesheng capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yixuesheng capsule (YXS) combined with recombination human erythropoietin (RHE)
Study: 16982228
Drug: Contraceptive patch
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive patch (EE 20 microg/day and norelgestromin 150 microg/day)
Study: 16982228
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (EE 35 microg and norgestimate 250 microg)
Study: 15208650
Drug: Amifostine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (1000 mg/day during conditioning)
Study: 1696671
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Digoxin and Quinapril
Study: 27889307
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TA) 15 mg/kg (Group B)
Study: 27889307
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TA) 10 mg/kg (Group C)
Study: 27889307
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TA) 30 mg/kg (Group A)
Study: 25894177
Drug: Dextrose in
Normalized name: dextrose in water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose in water plus insulin infusion (group 1)
Study: 25894177
Drug: Dextrose in
Normalized name: dextrose in water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose in water infusion (group 2)
Study: 17588810
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) treatment for one month
Study: 7843574
Drug: Psychiatric consultation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychiatric consultation letter providing treatment recommendations
Study: 30740133
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maintained daily routine activities without regular exercise)
Study: 24990423
Drug: 1.5 kcal/mL
Normalized name: lactose-reduced food 0.05 gram-1.5 kcal/mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 kcal/mL enteral nutrition solution
Study: 24990423
Drug: 1.0 kcal/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 kcal/mL enteral nutrition solution
Study: 22798383
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: 1.10 mL/kg for men and women
Study: 22798383
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: men 1.10 mL/kg, women 0.99 mL/kg
Study: 15734772
Drug: Adhesive patch
Normalized name: ADHESIVE PATCH, MEDICATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adhesive patch electrodes
Study: 15734772
Drug: Patch electrodes
Normalized name: ELECTRODE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch electrodes after cross-over
Study: 12390611
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous dipyrone
Study: 12390611
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL 0.9% physiological saline (placebo)
Study: 2214124
Drug: Oral ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ranitidine (0.4 mg.kg‐1)
Study: 2214124
Drug: Intramuscular ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ranitidine (0.1 mg.kg‐1)
Study: 26547662
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of metformin
Study: 26547662
Drug: Past use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Past use of metformin
Study: 24160184
Drug: Teacher professional
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teacher professional development (6 days) aimed at improving expressive and receptive oral language skills and early literacy; included school-based continuing contact and completion of a postgraduate unit on early language and literacy.
Study: 22677258
Drug: CAD106 50
Normalized name: CAD106
DrugBank: CAD106 (DB05150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAD106 50 μg
Study: 22677258
Drug: CAD106 150
Normalized name: CAD106
DrugBank: CAD106 (DB05150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAD106 150 μg
Study: 21125811
Drug: Chlortalidone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlortalidone (12.5 mg/day)
Study: 21125811
Drug: Trichlormethiazide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trichlormethiazide (1 mg/day)
Study: 15802115
Drug: Customary treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customary treatments (control group)
Study: 8840945
Drug: Nystatin tablets
Normalized name: Nystatin Tablets
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nystatin tablets 500,000 units four times a day
Study: 6434423
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acids infusion (group 1)
Study: 6434423
Drug: Combined essential
Normalized name: OILS,ESSENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined essential and non-essential amino acids infusion (group 2)
Study: 6434423
Drug: Routine laboratory
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine laboratory data and protein metabolism parameters (both groups)
Study: 27750364
Drug: Pneumatic unloader
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumatic unloader brace and conventional treatment
Study: 24417765
Drug: Drug used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug used for cardioversion (Propafenone vs Vernakalant)
Study: 19997723
Drug: High diuresis
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High diuresis (Group D) - pressure infusion of approximately 1 L of Ringer acetate solution and 20 mg of furosemide during a 30-40 min treatment session.
Study: 19012818
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day lisdexamfetamine
Study: 19012818
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day lisdexamfetamine
Study: 19012818
Drug: 70 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg/day lisdexamfetamine
Study: 15867832
Drug: Asthma education
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asthma education program (Open Airways) followed by 5 monthly visits with a nurse practitioner
Study: 31547503
Drug: Anthocyanin-rich antioxidant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanin-rich antioxidant juice (AJ), dosage: 240 mL twice-a-day for nine days
Study: 31547503
Drug: Placebo (PLA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA), dosage: 240 mL twice-a-day for nine days
Study: 21268098
Drug: Rectal distension
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal distension (150 ml of normal saline)
Study: 22275153
Drug: Rectal distension
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal distension
Study: 9782139
Drug: Preoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative administration of two injections of a depot formulation of leuprolide acetate 28 days apart
Study: 31295916
Drug: Maternal lipid‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal lipid‐based nutrient supplement (LNS)
Study: 27408987
Drug: Mushroom blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mushroom blend containing Cordyceps militaris (4 g·d‐1)
Study: 26009024
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of cotrimoxazole (CTX) prophylaxis
Study: 21298654
Drug: Atorvastatin 5
Normalized name: amlodipine-atorvastatin 5 mg-80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 5 mg/ezetimibe 5 mg
Study: 19026531
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (thiopental 4 mg/kg, succinylcholine 1-1.5 mg/kg, 1% end-tidal concentration of sevoflurane in nitrous oxide and 50% oxygen)
Study: 19026531
Drug: Neuraxial anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuraxial anesthesia (intrathecal 0.5% levobupivacaine 1.8-2.2 mL and epidural fentanyl 1 microg/kg)
Study: 16883221
Drug: Gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (600 mg b.i.d for 90 days)
Study: 15536776
Drug: Disulfiram (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disulfiram (1500 mg weekly in divided doses)
Study: 11421840
Drug: 75 mg/ml
Normalized name: urea 375 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/ml (7.5%) hypertonic saline (HS) administered at 1.6 ml/kg
Study: 11421840
Drug: 9 mg/ml
Normalized name: iodine 9 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg/ml normal saline administered at 13 ml/kg
Study: 11421840
Drug: 75 mg/ml
Normalized name: urea 375 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/ml (7.5%) hypertonic saline (HS)
Study: 11421840
Drug: 9 mg/ml
Normalized name: iodine 9 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg/ml normal saline
Study: 25629793
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide and isotonic nasal saline for 2 weeks
Study: 16977442
Drug: 80 ml
Normalized name: urinary bag 480 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 ml contrast material at 2.0 ml/s
Study: 16977442
Drug: 80 ml
Normalized name: urinary bag 480 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 ml contrast material followed by 40 ml saline at 2.0 ml/s
Study: 16977442
Drug: 60 ml
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ml contrast material at 1.5 ml/s
Study: 16977442
Drug: 60 ml
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 ml contrast material followed by 30 ml saline at 1.5 ml/s
Study: 16977442
Drug: Saline chaser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline chaser (40 ml or 30 ml)
Study: 15074087
Drug: Xuesaitong injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuesaitong injection (XSTI)
Study: 11190987
Drug: Choline chloride
Normalized name: Choline Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline chloride (2 g) added to usual TPN regimen
Study: 9613534
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.9% saline injected into the epidural catheter
Study: 9613534
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL 0.9% saline injected into the epidural catheter
Study: 8578840
Drug: Hib vaccine
Normalized name: ActHIB vaccine 0.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib vaccine mixed with whole‐cell DTP vaccine
Study: 8578840
Drug: Hib vaccine
Normalized name: ActHIB vaccine 0.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hib vaccine administered in separate limbs from whole‐cell DTP vaccine
Study: 2517007
Drug: Rilmenidine (RIL)
DrugBank: Rilmenidine (DB11738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine (RIL) 1 mg every morning or 1 mg twice daily if necessary
Study: 2517007
Drug: Methyldopa (MD)
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa (MD) 250 mg morning and evening or 500 mg twice daily if necessary
Study: 27684085
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL LMWF-5A
Study: 18058852
Drug: Escitalopram (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (mean dose 26.5 mg/day)
Study: 12626460
Drug: RNase L
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNase L 37-kDa/83-kDa ratio
Study: 11088083
Drug: Topical zanamivir
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical zanamivir (combined inhaled and intranasal zanamivir, inhaled zanamivir)
Study: 11088083
Drug: Intranasal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal and inhaled zanamivir
Study: 9052309
Drug: Inhaled anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled anesthesia (Group II)
Study: 1586184
Drug: Caffeine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (12.5 mg/kg loading dose and 3 mg/kg daily maintenance)
Study: 1586184
Drug: Caffeine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (25 mg/kg loading and 6 mg/kg daily maintenance)
Study: 1586184
Drug: Theophylline (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (7.5 mg/kg loading and 3 mg/kg thrice daily maintenance)
Study: 24457404
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg tid for 6 months
Study: 21168874
Drug: Testosterone 150
Normalized name: testosterone 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 150 mg + Dutasteride 0.25 mg
Study: 21168874
Drug: Testosterone 250
Normalized name: testosterone 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 250 mg + Dutasteride 0.25 mg
Study: 21168874
Drug: Testosterone 400
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone 400 mg + Dutasteride 0.25 mg
Study: 21168874
Drug: Testosterone 400
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone 400 mg
Study: 21168874
Drug: Dutasteride 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.25 mg
Study: 8694310
Drug: droperidol 0.65
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 0.65 mg i.v.
Study: 8694310
Drug: droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 1.25 mg i.v.
Study: 8694310
Drug: droperidol 0.65
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 0.65 mg i.v. and 1.25 mg i.v.
Study: 30453660
Drug: Dietary fiber
Normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fiber intake increased from 19 g/day to 29 g/day
Study: 27002500
Drug: HIVAX vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIVAX vaccine (replication-defective HIV-1 vaccine)
Study: 27002500
Drug: HIVAX vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIVAX vaccine
Study: 16641918
Drug: Chelation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chelation therapy with calcium disodium ethylenediaminetetraacetic acid (EDTA) weekly until body lead burden fell <60 microg for 3 months.
Study: 16641918
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group) received weekly placebo for 3 months.
Study: 7752916
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (TPN) with L-amino acid mixture, supplying 0.36 g N.kg‐1.d‐1
Study: 2300922
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of methylprednisolone (HDC)
Study: 22289557
Drug: 2 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg/kg fentanyl bolus
Study: 22289557
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of fentanyl 0.5 μg/kg followed by 1.5 μg/kg after 1 min
Study: 22289557
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of fentanyl 0.5 μg/kg followed by 1.5 μg/kg after 2 min
Study: 22289557
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of fentanyl 0.5 μg/kg followed by 1.5 μg/kg after 3 min